 SUZHOU and SHANGHAI, China, May 10, 2021 PRNewswire -- Gracell Biotechnologies Inc. NASDAQ: GRCL Gracell, a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Dr. Jenny Yajin Ni as its Chief Technology Officer CTO. In her role, Dr. Ni will be responsible for strategically leading CAR-T product development, Chemistry, Manufacturing, and Control CMC, and supply chain management activities. 